News

(Bloomberg) -- Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US Food and Drug Administration, offering patients ...
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. Into this crowded treatment landscape comes another new medicine as the FDA has signed off ...
Also Read: Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal By lowering AT, a protein that inhibits blood clotting, Qfitlia helps increase thrombin generation ...
The FDA granted the approval of Qfitlia to Sanofi (SNY). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best ...
Sanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the antithrombin-lowering therapy is indicated for use as a prophylactic treatment ...
Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...
Siemens Healthineers Qfitila will support people living with hemophilia A or B, with or without inhibitors, by helping to rebalance one of the body’s critical clotting mechanisms to prevent ...
This program is for patients prescribed Qfitlia or other hemophilia treatments from Sanofi's portfolio. The FDA granted Qfitlia Orphan Drug Designation for hemophilia A and B, Fast Track ...
Sanofi's Qfitlia, approved a few days ago by the FDA, offers a competitive edge in the hemophilia market with fewer injections and broader applicability than rivals. Despite Qfitlia's promising ...